Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Karyopharm Therapeutics Inc. (KPTI) SEC filings page provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Karyopharm is a commercial-stage pharmaceutical company listed on the Nasdaq Global Select Market, and its filings detail financial results, financing arrangements and key corporate developments related to its oncology-focused business.
Among the most relevant documents for investors are Form 10-K annual reports and Form 10-Q quarterly reports, which summarize financial performance, risk factors and updates on Karyopharm’s commercial product XPOVIO (selinexor) and its clinical pipeline in multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL). These periodic reports typically discuss revenue from U.S. XPOVIO net product sales and license and royalty revenue from partners, as described in the company’s public communications.
The company also files numerous Form 8-K current reports to describe material events. Recent 8-K filings referenced in the provided information include disclosures of quarterly financial results, strategic financing transactions involving senior secured term loans and 9.00% convertible senior notes due 2028 and 2029, and the issuance of equity and warrants in private placements. Other 8-Ks cover topics such as board changes, workforce reductions and the provision of “cleansing materials” to potential investors during financing discussions.
Investors tracking capital structure and liquidity can review exhibits to these filings, which describe credit and guaranty agreements, note purchase agreements, warrant terms and registration rights agreements. For governance and compensation matters, additional filings may include proxy statements and equity award disclosures, such as inducement grants reported under Nasdaq Listing Rule 5635(c)(4).
On this page, Stock Titan supplements raw EDGAR documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand changes in debt, equity, cash runway expectations, and updates on Karyopharm’s clinical and commercial programs. Real-time updates ensure that new 10-Ks, 10-Qs, 8-Ks and other forms appear as they are filed, while specialized views can surface insider-related forms such as Form 4 when available.
Karyopharm Therapeutics amended its credit agreement and entered a broad forbearance arrangement to manage liquidity while it continues to face substantial doubt about its ability to continue as a going concern. The changes aim to extend its cash runway beyond the second quarter of 2026 and past expected top-line data from the Phase 3 XPORT-EC 042 trial, if conditions are met.
The amendment allows June 30, 2026 cash interest under the credit facility to be paid in kind and moves a June 10, 2026 principal payment to September 10, 2026 if the company raises at least $25.0 million in common stock proceeds before June 10, 2026, defined as the Capital Raise Trigger. It keeps the minimum consolidated liquidity covenant at $10.0 million through October 10, 2026, excluding qualifying equity proceeds from increasing that threshold, and extends a 5% prepayment premium potentially through May 8, 2027.
Through a separate forbearance agreement, all lenders, holders of the company’s 9.00% convertible notes due 2028 and 2029, and the revenue interest investors agree, once the Capital Raise Trigger occurs, to temporarily refrain from exercising certain rights related to missed June 30, 2026 cash interest payments and related minimum liquidity covenant issues, with forbearance periods running to September 30, 2026 and October 10, 2026, respectively.
Karyopharm Therapeutics Inc. obtained stockholder approval at a special meeting to significantly increase its authorized share capital. The amendment raises total authorized capital stock from 58,333,333 to 111,000,000 shares and authorized common stock from 53,333,333 to 106,000,000 shares.
The Authorized Shares Proposal passed with 9,436,123 votes for, 3,213,329 against and 25,465 abstaining. A related adjournment proposal was also approved but not used. The company filed a Certificate of Amendment in Delaware on February 18, 2026 to put the share increase into effect.
Karyopharm Therapeutics EVP and Chief Development Officer Poulton Stuart reported an automatic sale of company stock. On February 17, 2026, a broker-assisted transaction sold 378 shares of common stock at $8.63 per share to cover withholding taxes triggered by vesting restricted stock units.
The sale was executed under a durable automatic sale instruction plan adopted on May 18, 2022 and is described as non-discretionary for the insider. Following this tax-related sale, Poulton Stuart directly holds 99,429 shares of Karyopharm Therapeutics common stock.
T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G reporting beneficial ownership of 2,244,421 shares of THERAPEUTICS INC common stock, representing 11.8% of the class as of the event date December 31, 2025.
The firm reports sole voting and dispositive power over 1,491,409 shares and no shared voting or dispositive power. It states that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control, and expressly denies beneficial ownership beyond what is required to be reported.
Karyopharm Therapeutics reports 2025 revenue of $146.1 million, mainly from XPOVIO multiple myeloma sales of $114.9 million and $31.2 million of license revenue. The company remains deeply loss-making, with a 2025 net loss of $196.0 million and an accumulated deficit of $1.8 billion.
Cash, cash equivalents and investments were $63.7 million as of December 31, 2025, while substantial term loans, convertible notes and revenue interest obligations remain outstanding. Management concludes there is substantial doubt about the ability to continue as a going concern within one year after the financial statements are issued.
To gain liquidity, Karyopharm completed October 2025 financing transactions that added $27.5 million of new debt, deferred $25.4 million of payments and equitized portions of convertible notes via new shares and warrants, but also increased dilution. The company continues to invest in late-stage trials for selinexor in myelofibrosis, endometrial cancer and multiple myeloma while relying heavily on XPOVIO sales and partner royalties.
Adage Capital Management and related principals report a 2.38% stake in Karyopharm Therapeutics Inc. common stock. The Reporting Persons beneficially own 436,736 shares, including 15,414 shares issuable upon exercise of warrants. This percentage is based on 18,310,283 shares outstanding as of December 29, 2025.
They state the holdings are maintained in the ordinary course of business and not for the purpose of changing or influencing control of Karyopharm. All voting and dispositive power over these shares is shared among the Reporting Persons, with no sole voting or dispositive authority reported.
Karyopharm Therapeutics reported essentially flat 2025 revenue while remaining deeply loss-making and heavily leveraged. Total revenue was $146.1 million, up slightly from $145.2 million, with U.S. XPOVIO net product revenue of $114.9 million. Loss from operations improved to $90.7 million from $119.4 million as R&D and SG&A were reduced, but net loss widened sharply to $196.0 million, driven largely by a $62.4 million loss on extinguishment of debt and higher interest expense.
Cash, cash equivalents, restricted cash and investments fell to $64.1 million at year-end 2025, and the company expects its existing liquidity plus cash flows to fund operations only into the second quarter of 2026. For 2026, Karyopharm guides total revenue to $130–$150 million and U.S. XPOVIO net product revenue to $115–$130 million, against planned R&D and SG&A of $230–$245 million, implying continued operating losses.
Strategically, management highlights late-stage pipeline catalysts: top-line data from the Phase 3 SENTRY myelofibrosis trial expected in March 2026, and top-line data from the Phase 3 XPORT-EC-042 endometrial cancer trial expected in mid-2026, positioning 2026 as a pivotal year for selinexor’s potential label and revenue expansion.
Karyopharm Therapeutics Inc. received a Schedule 13G filing showing that hedge fund–related entities have become significant shareholders of its common stock.
Integrated Core Strategies (US) LLC reports beneficial ownership of 997,577 shares, or 5.4% of the common stock. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 1,008,662 shares, or 5.5% of the class, with shared voting and dispositive power and no sole authority.
The filers certify that the shares were not acquired to change or influence control of Karyopharm, but instead are held on a passive investment basis.
Karyopharm Therapeutics Inc. reported that its President and CEO, Richard A. Paulson, received an award of 81,060 shares of common stock in the form of restricted stock units (RSUs) on February 5, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan and increase his directly held beneficial ownership to 279,391 shares of common stock.
The RSUs convert into common stock on a one-for-one basis. Vesting is scheduled so that 50% of the RSUs vest on January 31, 2027, with the remaining 50% vesting on January 31, 2028, tying a portion of the CEO’s compensation to the company’s long-term performance and continued service.
Karyopharm Therapeutics executive Lori Macomber reported an automatic tax-related stock sale. On 02/03/2026, the EVP, CFO & Treasurer sold 1,626 shares of Karyopharm Therapeutics Inc. common stock at $6.30 per share in a broker-assisted transaction tied to restricted stock unit vesting. After the sale, she directly beneficially owned 85,105 common shares. The filing explains the transaction was executed under a durable automatic sale instruction plan adopted on December 19, 2024, solely to cover withholding tax liabilities and did not represent a discretionary trade.